Evidence for the Study of Acute, Irritative Dry Cough Symptoms
This section will summarize the research base on this medicine, focusing on the available Randomized Controlled Trials (RCTs) and comparative studies that have examined how cough frequency and severity were monitored in both adult and pediatric patients.
Butamirate citrate was studied for conditions characterized by fluctuating or episodic manifestations of non-productive cough, such as those associated with acute bronchitis or tracheitis. Research on this medicine largely involves short-term Randomized Controlled Trials (RCTs) and comparative studies where the medicine was evaluated in adults and children experiencing these symptoms. Studies researched how often and how severely coughing episodes evolved in the observed populations.
Short-term trials described the patterns of how symptoms evolved in the observed populations over brief treatment periods, often lasting only a few days. Findings from these clinical studies describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level, particularly focusing on patient-reported outcomes describing perceived discomfort related to nighttime coughing. Some research also examined the body's cough reflex sensitivity during the study period using objective laboratory tests in healthy volunteers; however, the data from these highly controlled models was observed in some studies to be mixed when compared to the patterns reported in clinical trials.
Because acute cough often resolves quickly on its own, and because of a large natural variation in symptoms, it may be challenging for researchers to isolate patterns related to the study variables. Furthermore, many of the clinical trials conducted for this type of antitussive medicine are historical studies that evidence quality varies across studies when compared to modern methodological standards. Therefore, while research contributes to understanding symptom patterns over defined time intervals, the overall certainty remains low due to the nature of the condition being studied and the age of some of the evidence.
How Studies Measured Cough Relief
This sub-section will clarify the specific methods used by researchers to assess the medicine's role, including the use of subjective patient-reported measures and objective laboratory testing of the cough reflex.
In many studies, the most important outcome was monitored through patient-reported outcomes describing perceived discomfort. Patients and investigators were evaluated in trials assessing short-term or episodic symptom patterns by tracking the frequency and perceived intensity of the cough. This type of measurement is applied in studies examining patient-reported experiences but can be influenced by subjective factors.
In addition to patient reports, research examined outcomes monitoring physiological strain or stress by using specialized laboratory tests, such as the capsaicin challenge model. This method was studied for assessing the baseline level of irritation needed to trigger a cough reflex. These objective measures were observed in healthy volunteers and evidence contributes to understanding symptom patterns related to neurological control of the cough.
Evidence for Use in Specialized Clinical Situations
This section will outline the structure of the evidence for the medicine’s role in contexts beyond typical acute respiratory infections, such as its described use in procedures where cough outcomes are a factor, and for patients with chronic cough or cough associated with malignancies.
Kreval Forte was evaluated in specific niche medical settings. This includes its use in research contexts involving fluctuating or unstable symptoms where it was monitored before or after surgery (pre-operative and post-operative) or during diagnostic procedures like bronchoscopy. Research also explored its application in specific populations such as those with conditions characterized by fluctuating or episodic manifestations including chronic cough or cough linked to inflammatory or irritative states associated with malignancies.
The evidence for these specialized uses is distinct from the acute cough trials. This research is primarily derived from small-scale comparative trials and observational settings evaluating daily-life functioning. These studies described patterns observed in the studies related to outcomes related to physical discomfort (such as cough frequency and intensity) in the specific population being observed in.
However, for these specialized uses, the evidence is limited and the certainty remains low. The data for certain groups remain insufficient, particularly for patients with cough related to malignancy. The available studies are often older and provide limited information for long-term outcomes or consistency across various institutions.
Research in Specific Patient Groups
This section will detail the available studies concerning specific demographics, focusing on the research that has evaluated the use of the medicine in children and in older adults, and highlighting any limitations in data for these groups.
Butamirate citrate was evaluated in specific demographic groups. Research examined its application in children included in short-term comparative trials. Studies also explored the patterns of its use in older adults where outcomes related to physical discomfort and daily functioning were monitored.
Studies report how symptoms evolved in the observed populations over a defined time interval. However, the sample sizes were modest in many of the trials focused specifically on these age groups.
The data for certain groups remain insufficient to draw wide-ranging conclusions. While the medicine was studied for different age groups, the available evidence may not fully represent the range of health conditions or coexisting medications common in the older adult population.
Study Duration and Long-Term Follow-up
This section will summarize what the research shows regarding the duration of studies that support the use of the medicine, clarifying what is known and unknown about the persistence of patterns beyond the short-term study period.
The majority of clinical research on this drug examined acute cough, meaning the trials focused on episodes where symptoms become more noticeable over a short-term span, usually no more than 5 days. Research examined outcomes describing episodic or acute changes during these brief periods to see how symptoms evolved.
Because of this short-term focus, the long-term effects are not fully established and long-term outcomes are not well characterized. Research does not determine whether using the medicine was associated with any specific patterns related to the recurrence of cough or other sustained outcomes related to systemic or functional imbalance. The follow-up durations were limited across the primary body of evidence.
Evidence Consistency and Remaining Research Gaps
This section will synthesize the main points of uncertainty within the research record, summarizing where study findings may be inconsistent (e.g., between subjective clinical trials and objective laboratory models) and where regulators or scientific bodies have identified key areas where more data is needed.
Scientific reviews and regulatory reports indicate patterns related to several persistent research limitation frames for this medicine. The evidence quality varies across studies, with many supporting trials being quite old. Furthermore, findings were mixed when comparing clinical observations, which applied in studies examining patient-reported experiences, to results from objective cough reflex challenge studies conducted in the laboratory.
Comparative evidence is limited for certain patient subgroups, and the subgroup findings are uncertain. Specific patient populations and specialized clinical needs remain areas where data are still emerging and research is ongoing. The limitations highlight that study results apply only to the populations studied and reflect the specific, often short-term, conditions under which they were observed in.
Key Studies & References
Risk Management Plan: The effect of butamirate versus dextromethorphan was studied in patients with irritable cough (Danish Medicines Agency)
